The studies investigating the relationship between PD-L1 expression in tumor cellsand clinical features in anogenital and oropharyngeal squamous cell carcinomas(SCCs) are growing [9–29], which could identify potential pathologicalcharacteristics for judging whether patients could get clinical benefits from PD-1or PD-L1 blockade therapy with variable PD-L1 expression and investigate the role ofPD-L1 in anogenital and oropharyngeal SCC. This evidence concerns the gene CD274 and neoplasm.